Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Authors = Faisal Alsuwayyid ORCID = 0000-0001-7969-1809

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
11 pages, 1055 KiB  
Review
Practical Guide for Anticoagulant and Antiplatelet Reversal in Clinical Practice
by Mohammed Aldhaeefi, Hisham A. Badreldin, Faisal Alsuwayyid, Tariq Alqahtani, Omar Alshaya, Majed S. Al Yami, Khalid Bin Saleh, Shmeylan A. Al Harbi and Abdulrahman I. Alshaya
Pharmacy 2023, 11(1), 34; https://doi.org/10.3390/pharmacy11010034 - 11 Feb 2023
Cited by 12 | Viewed by 34357
Abstract
In recent years, anticoagulant and antiplatelet use have increased over the past years for the prevention and treatment of several cardiovascular conditions. Due to the rising use of antithrombotic medications and the complexity of specific clinical cases requiring such therapies, bleeding remains the [...] Read more.
In recent years, anticoagulant and antiplatelet use have increased over the past years for the prevention and treatment of several cardiovascular conditions. Due to the rising use of antithrombotic medications and the complexity of specific clinical cases requiring such therapies, bleeding remains the primary concern among patients using antithrombotics. Direct oral anticoagulants (DOACs) include rivaroxaban, apixaban, edoxaban, and betrixaban. Direct thrombin inhibitors (DTIs) include argatroban, bivalirudin, and dabigatran. DOACs are associated with lower rates of fatal, life-threatening, and significant bleeding risks compared to those of warfarin. The immediate reversal of these agents can be indicated in an emergency setting. Antithrombotic reversal recommendations are still in development. Vitamin K and prothrombin complex concentrate (PCCs) can be used for warfarin reversal. Andexanet alfa and idarucizumab are specific reversal agents for DOACs and DTIs, respectively. Protamine sulfate is the solely approved reversal agent for unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH). However, there are no specific reversal agents for antiplatelets. This article aims to provide a practical guide for clinicians regarding the reversal of anticoagulants and antiplatelets in clinical practice based on the most recent studies. Full article
(This article belongs to the Special Issue Pharmacy: State-of-the-Art and Perspectives in USA)
Show Figures

Figure 1

Back to TopTop